Consun Pharmaceutical Group Ltd. (HK:1681)
:1681
Want to see HK:1681 full AI Analyst Report?
Top Page
Consun Pharmaceutical Group Ltd.
(1681)
Select Model
Select Model
Rating:76Outperform
Price Target:
HK$16.50
▲(1.16% Upside)
Action:Reiterated
Date:05/01/26
The score is driven primarily by strong financial performance (high, stable margins; low leverage; strong ROE) and supportive valuation (modest P/E plus a solid dividend yield). These positives are tempered by weaker near-term technicals (below key moving averages with negative MACD), suggesting momentum is currently unfavorable.
Positive Factors
High & stable profitability
Consun’s consistently high gross and net margins reflect durable pricing power and tight cost control across its specialty drug portfolio. Sustained margins support reinvestment in R&D and manufacturing, underpin reliable internal funding for growth and steady shareholder returns over the medium term.
Negative Factors
Uneven FCF growth and cash-conversion gaps
Intermittent negative free cash flow years and missing/zero 2025 cash-conversion ratios reduce visibility on the durability of earnings-to-cash conversion. This uncertainty complicates forecasting of sustainable distributable cash and long-term investment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
High & stable profitability
Consun’s consistently high gross and net margins reflect durable pricing power and tight cost control across its specialty drug portfolio. Sustained margins support reinvestment in R&D and manufacturing, underpin reliable internal funding for growth and steady shareholder returns over the medium term.
Read all positive factors
Consun Pharmaceutical Group Ltd. (1681) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$11.92B
Dividend Yield3.93%
Average Volume (3M)2.00M
Price to Earnings (P/E)5.2
Beta (1Y)0.57
Revenue Growth15.28%
EPS Growth14.76%
CountryHK
Employees3,164
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.27
Shares Outstanding841,547,100
10 Day Avg. Volume1,421,042
30 Day Avg. Volume1,998,301
Financial Highlights & Ratios
PEG Ratio0.77
Price to Book (P/B)2.65
Price to Sales (P/S)3.52
P/FCF Ratio10.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$24.23Price Target Upside48.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.43
Revenue Forecast (FY)HK$3.88B
Consun Pharmaceutical Group Ltd. Business Overview & Revenue Model
Company Description
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segment...
How the Company Makes Money
null...
Consun Pharmaceutical Group Ltd. Financial Statement Overview
Summary
Income Statement
92
Very Positive
Balance Sheet
94
Very Positive
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.42B | 2.97B | 2.59B | 2.34B | 2.04B |
| Gross Profit | 2.67B | 2.24B | 1.92B | 1.76B | 1.53B |
| EBITDA | 1.21B | 1.05B | 963.06M | 785.89M | 728.71M |
| Net Income | 1.08B | 910.46M | 784.53M | 682.91M | 590.17M |
Balance Sheet | |||||
| Total Assets | 6.41B | 5.85B | 5.51B | 4.89B | 4.36B |
| Cash, Cash Equivalents and Short-Term Investments | 3.95B | 3.87B | 3.58B | 3.04B | 2.43B |
| Total Debt | 213.01M | 267.17M | 511.53M | 460.18M | 610.97M |
| Total Liabilities | 1.56B | 1.46B | 1.59B | 1.45B | 1.45B |
| Stockholders Equity | 4.54B | 4.10B | 3.63B | 3.15B | 2.62B |
Cash Flow | |||||
| Free Cash Flow | 1.14B | 977.99M | 766.41M | 896.09M | 627.29M |
| Operating Cash Flow | 1.21B | 1.09B | 818.97M | 947.68M | 725.54M |
| Investing Cash Flow | -2.15B | -186.91M | -231.77M | -368.80M | -298.31M |
| Financing Cash Flow | -711.74M | -729.26M | -280.10M | -342.20M | -166.66M |
Consun Pharmaceutical Group Ltd. Technical Analysis
Negative
16.31
Price Trends
16.27
Negative
16.68
Negative
15.82
Negative
Market Momentum
-0.45
Positive
36.33
Neutral
20.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1681, the sentiment is Negative. The current price of 16.31 is above the 20-day moving average (MA) of 15.49, above the 50-day MA of 16.27, and above the 200-day MA of 15.82, indicating a bearish trend. The MACD of -0.45 indicates Positive momentum. The RSI at 36.33 is Neutral, neither overbought nor oversold. The STOCH value of 20.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1681.
Consun Pharmaceutical Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | HK$6.49B | 4.42 | 11.90% | 5.80% | -17.03% | 12.82% | |
76 Outperform | HK$11.92B | 5.21 | 24.04% | 3.93% | 15.28% | 14.76% | |
58 Neutral | HK$9.48B | 11.74 | 5.02% | 4.47% | 5.91% | -40.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$8.11B | -10.27 | -1.64% | 3.66% | -10.68% | -737.07% | |
50 Neutral | HK$9.98B | 34.17 | 3.49% | 0.87% | 37.90% | ― |
* Healthcare Sector Average
HK:1681
Consun Pharmaceutical Group Ltd.
14.76
5.49
59.31%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.63
-0.45
-21.52%
HK:0460
Sihuan Pharmaceutical Holdings Group
1.11
0.30
36.36%
HK:2877
China Shineway Pharmaceutical Group Limited
8.58
1.71
24.95%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
6.24
0.48
8.41%
Consun Pharmaceutical Group Ltd. Corporate Events
Consun Pharmaceutical Sets AGM to Approve 2025 Results, Dividend and Share Issue Mandate
Apr 27, 2026
Consun Pharmaceutical Group Ltd. has called its 2026 annual general meeting for May 26 in Hong Kong, to be held in a hybrid physical and virtual format, to consider approval of the 2025 audited financial statements, director re-elections and remun...
Consun Pharmaceutical Posts Double-Digit Profit Growth and Raises Shareholder Payout
Mar 26, 2026
Consun Pharmaceutical Group reported a solid set of annual results for the year ended 31 December 2025, with revenue rising 15.2% to RMB3.42 billion and gross profit improving as cost of sales grew more slowly than topline. Net profit attributable...
Consun Pharmaceutical Declares HKD 0.4 Final Dividend for 2025
Mar 26, 2026
Consun Pharmaceutical Group Limited has declared a final ordinary cash dividend of HKD 0.4 per share for the financial year ended 31 December 2025, signaling confidence in its financial performance and cash generation. Subject to shareholder appro...
Consun Pharma Sets March Board Meeting to Approve 2025 Results and Consider Dividend
Mar 5, 2026
Consun Pharmaceutical Group Limited has scheduled a board meeting for 26 March 2026 to review and approve its audited consolidated financial statements for the year ended 31 December 2025 and to clear the related results announcement for publicati...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.